Literature DB >> 9371364

Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins.

T Deguchi1, M Yasuda, M Nakano, S Ozeki, E Kanematsu, Y Nishino, Y Kawada.   

Abstract

MICs of DU-6859a, a novel fluoroquinolone, for 18 Klebsiella pneumoniae isolates and 21 Enterobacter cloacae isolates with altered GyrA or altered GyrA and ParC ranged from < or =0.025 to 6.25 microg/ml and from 0.1 to 3.13 microg/ml, respectively. Based on the MICs at which 90% of the isolates were inhibited for these strains of K. pneumoniae and E. cloacae, DU-6859a exhibited 16- to 256-fold-greater activity than currently available fluoroquinolones.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9371364      PMCID： PMC164159     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.

Authors:  M Nakashima; T Uematsu; K Kosuge; K Umemura; H Hakusui; M Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC.

Authors:  M Georgiou; R Muñoz; F Román; R Cantón; R Gómez-Lus; J Campos; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

3.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.

Authors:  P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

4.  Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.

Authors:  T Deguchi; M Yasuda; M Nakano; S Ozeki; T Ezaki; I Saito; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

5.  Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.

Authors:  Y Kumagai; J I Kato; K Hoshino; T Akasaka; K Sato; H Ikeda
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.

Authors:  M Tanaka; K Hoshino; M Hohmura; H Ishida; A Kitamura; K Sato; I Hayakawa; T Nishino
Journal:  J Antimicrob Chemother       Date:  1996-06       Impact factor: 5.790

7.  Topoisomerase IV is a target of quinolones in Escherichia coli.

Authors:  A B Khodursky; E L Zechiedrich; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

8.  Mechanism of action of quinolones against Escherichia coli DNA gyrase.

Authors:  H Yoshida; M Nakamura; M Bogaki; H Ito; T Kojima; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

Authors:  P Heisig; H Schedletzky; H Falkenstein-Paul
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.

Authors:  A Kitamura; K Hoshino; Y Kimura; I Hayakawa; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
View more
  6 in total

1.  Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.

Authors:  H Mouneimné; J Robert; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production.

Authors:  Luis Martínez-Martínez; Alvaro Pascual; María del Carmen Conejo; Isabel García; Providencia Joyanes; Antonio Doménech-Sánchez; Vicente Javier Benedí
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii.

Authors:  Xiaomeng Dong; Fengzhe Chen; Yajun Zhang; Haihong Liu; Yongjuan Liu; Lixian Ma
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  Alteration of GyrA amino acid required for ciprofloxacin resistance in Klebsiella pneumoniae isolates in China.

Authors:  Yingmei Fu; Lishuang Guo; Yan Xu; Wenli Zhang; Jiaao Gu; Jianfeng Xu; Xiaobei Chen; Yuehui Zhao; Jiayu Ma; Xinghan Liu; Fengmin Zhang
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

5.  Genotypes of Klebsiella oxytoca isolates from patients with nosocomial pneumonia are distinct from those of isolates from patients with antibiotic-associated hemorrhagic colitis.

Authors:  Kathrin A T Herzog; Georg Schneditz; Eva Leitner; Gebhard Feierl; Karl Martin Hoffmann; Ines Zollner-Schwetz; Robert Krause; Gregor Gorkiewicz; Ellen L Zechner; Christoph Högenauer
Journal:  J Clin Microbiol       Date:  2014-03-05       Impact factor: 5.948

6.  Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii.

Authors:  Nannan Xu; Gang Wang; Yan Leng; Xiaomeng Dong; Fengzhe Chen; Quantai Xing
Journal:  Exp Ther Med       Date:  2018-08-20       Impact factor: 2.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.